Related Experiment Video
Updated: Jul 12, 2026
Purification of Human S100A12 and Its Ion-induced Oligomers for Immune Cell Stimulation
Published on: September 29, 2019
Theoretical study on binding of S100B protein
Artur Gieldon1, Mattia Mori, Rebecca Del Conte
1Protera S. r. l., Viale delle Idee, 22, 50019, Sesto Fiorentino, Fi, Italy. gieldon@proterasrl.com
Abstract:
S100B protein is one of the factors involved in the down-regulation of tumor suppressor protein p53, a transcription activator that signals for cycle arrest and apoptosis. As the inactivation of normal p53 functions is found in over half of human cancers, restoration of normal p53 functions through the destruction or prevention of S100B--p53 complexes represents a possible approach for the development of anti-cancer drugs. The aim of this work was to propose the S100B binding interface through an examination of the literature and use of molecular modeling (MM) techniques with AutoDock program and the AMBER force field. We propose two residues in the S100B binding pocket (Val56, Phe76) and two residues on the protein surface (Val52, Ala83) are essential for ligand binding. The data presented here indicate that interactions with these four residues are necessary for a reduction in the incidence of the S100B--p53 complex. Additionally, we have tried to explain a mechanism for the action of pentamidine, the best-known S100B ligand, and have proposed two S100B--pentamidine structures. The results presented here may be useful for the efficient design of new S100B ligands.
Insights
Researchers identified key residues on S100B protein essential for binding to tumor suppressor p53. This finding aids in developing new anti-cancer drugs by targeting S100B-p53 complexes.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- S100B protein down-regulates tumor suppressor p53, a critical factor in cell cycle arrest and apoptosis.
- Inactivation of p53 is implicated in over half of human cancers, making its restoration a therapeutic target.
- Disrupting S100B-p53 complexes offers a potential strategy for anti-cancer drug development.
Purpose of the Study:
- To elucidate the S100B binding interface for p53.
- To identify specific residues involved in S100B-p53 complex formation.
- To propose mechanisms for S100B ligand interactions, such as with pentamidine.
Main Methods:
- Literature review to gather existing data on S100B and p53 interactions.
- Molecular modeling (MM) techniques utilizing the AutoDock program.
- Application of the AMBER force field for computational analysis.
Main Results:
- Identified four key residues (Val56, Phe76, Val52, Ala83) essential for S100B ligand binding.
- Demonstrated that interactions with these residues are crucial for reducing S100B-p53 complex formation.
- Proposed two distinct S100B-pentamidine complex structures and elucidated pentamidine's mechanism of action.
Conclusions:
- The identified S100B binding interface provides critical insights for anti-cancer drug design.
- Targeting specific residues on S100B can disrupt the S100B-p53 complex, potentially restoring p53 function.
- These findings facilitate the rational design of novel S100B ligands with therapeutic potential.
Related Concept Videos
02:18The Equilibrium Binding Constant and Binding Strength
02:40Ligand Binding Sites
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In contrast,...